EUVIMEDEUVIMED entdecken
Open Access

Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity

Z Zack Ma iD, Natalie J Guzikowski, Ji-Woon Kim iD, Ege T Kavalali iD, Lisa M Monteggia iD

Science · 08.05.2025 · 388 (6747) · 646-655

DOI: 10.1126/science.abb6748 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 08.05.2025. Verfasst von Z Zack Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Vanderbilt University, Nashville, TN, USA. Hauptthemen laut MEDLINE: Antidepressive Agents, Dual Specificity Phosphatase 6, Extracellular Signal-Regulated MAP Kinases, Ketamine. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repeated ketamine treatment to maintain a rapid antidepressant effect can lead to side effects over time, highlighting an unmet clinical need for sustaining this drug’s antidepressant action from a single administration. Ketamine-induced synaptic potentiation at CA3-CA1 synapses has been proposed to be a key synaptic substrate for antidepressant action. Here, we found that ketamine-induced CA3-CA1 synaptic potentiation could be augmented by transiently increasing extracellular signal–regulated kinase (ERK) activity through pharmacological inhibition of dual-specificity phosphatases 6 (DUSP6). The antidepressant-like behavioral effects of acute ketamine treatment were extended by DUSP6 inhibition for up to 2 months. The selective deletion of tropomyosin receptor kinase B (TrkB) in excitatory neurons abolished these DUSP6 inhibition–mediated synaptic and behavioral effects. These data suggest that ketamine’s rapid antidepressant effects can be sustained by selectively targeting downstream intracellular signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsDual Specificity Phosphatase 6Extracellular Signal-Regulated MAP KinasesKetamineNeuronal PlasticityAnimalsFemaleMaleMiceCA1 Region, HippocampalDepressionMAP Kinase Signaling SystemMembrane GlycoproteinsMice, Inbred C57BLNeuronsReceptor, trkBSynapsesHumans

Substanzen

Antidepressive AgentsDual Specificity Phosphatase 6Extracellular Signal-Regulated MAP KinasesKetamineMembrane GlycoproteinsNtrk2 protein, mouseReceptor, trkB

Autor:innen und Institutionen

  • Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.
  • Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA.

ORCID-Profile: Z Zack Ma, Ji-Woon Kim, Ege T Kavalali, Lisa M Monteggia

Förderung

  • NIMH NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Ma, Z. Z., Guzikowski, N. J., Kim, J. W., Kavalali, E. T., & Monteggia, L. M. (2025). Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity. Science, 388(6747), 646-655. https://doi.org/10.1126/science.abb6748

Vancouver

Ma ZZ, Guzikowski NJ, Kim JW, Kavalali ET, Monteggia LM. Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity. Science. 2025;388(6747):646-655. doi:10.1126/science.abb6748

BibTeX
@article{Ma2025,
  author = {Ma, Z Zack and Guzikowski, Natalie J and Kim, Ji-Woon and Kavalali, Ege T and Monteggia, Lisa M},
  title = {Enhanced ERK activity extends ketamine’s antidepressant effects by augmenting synaptic plasticity},
  journal = {Science},
  year = {2025},
  volume = {388},
  number = {6747},
  pages = {646--655},
  doi = {10.1126/science.abb6748}
}
Kostenlos starten →